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Purpose: We sought to determine whether an association study using information
contained in clinical notes could identify known and potentially novel risk factors for
nonadherence to antihypertensive medications.
Methods: We conducted a retrospective concept‐wide association study (CWAS)
using clinical notes to identify potential risk factors for medication nonadherence,
adjusting for age, sex, race, baseline blood pressure, estimated glomerular filtration
rate, and a combined comorbidity score. Participants included Medicare beneficiaries
65 years and older receiving care at the Harvard Vanguard Medical Associates net-
work from 2010‐2012 and enrolled in a Medicare Advantage program. Concepts
were extracted from clinical notes in the year prior to the index prescription date
for each patient. We tested associations with the outcome for 5013 concepts
extracted from clinical notes in a derivation cohort (4382 patients) and accounted
for multiple hypothesis testing by using a false discovery rate threshold of less than
5% (q < .05). We then confirmed the associations in a validation cohort (3836
patients). Medication nonadherence was defined using a proportion of days covered
(PDC) threshold less than 0.8 using pharmacy claims data.
Results: We found 415 concepts associated with nonadherence, which we orga-
nized into 11 clusters using a hierarchical clustering approach. Volume depletion
and overload, assessment of needs at the point of discharge, mood disorders, neuro-
logical disorders, complex coordination of care, and documentation of noncompliance
were some of the factors associated with nonadherence.
Conclusions: This approach was successful in identifying previously described and
potentially new risk factors for antihypertensive nonadherence using the clinical
narrative.
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KEY POINTS
• We conducted a retrospective concept‐wide association
study using clinical notes to identify potential risk
factors for medication nonadherence.
• We found 415 concepts associated with nonadherence
after adjusting for age, sex, race, baseline blood
pressure, estimated glomerular filtration rate, and a
combined comorbidity score, which we organized into
11 clusters.
• Volume depletion and overload, assessment of needs at
the point of discharge, mood disorders, neurological
disorders, complex coordination of care, and
documentation of noncompliance were some of the
factors associated with nonadherence.
SINGH ET AL.13001 | INTRODUCTION
Adherence, defined as the extent to which patients take medications
as prescribed,1 is often poor for antihypertensive medications2 and is
associated with worse health outcomes, including increased all‐cause
mortality,3 cardiovascular mortality,4,5 and stroke severity.6 A US
survey of hypertensive adults found that 30.5% of respondents
self‐identified as being nonadherent to hypertensive medications.7
Other studies8,9 have reported the prevalence of nonadherence
between 16% and 52%, though the rates depend on hownonadherence
is measured.10
Adherence is also a complex health behavior, and understanding
the reasons why people do not consistently take prescribed medica-
tions has been a topic of intense study. Many systematic reviews have
been conducted and have identified several factors that account for
nonadherence.11-15 In one of these reviews, Krueger and colleagues13
grouped the reasons contributing to adherence behaviors into five
categories: patient demographic‐related factors (eg, low literacy), psy-
chological and behavioral characteristics, treatment plan issues,
disease‐related issues (eg, severity of illness), and health care system
issues (eg, relationship with provider and access to care). Psychological
and behavioral characteristics linked to nonadherence include a belief
that a medication is unimportant or harmful, depression, impaired
cognitive function, forgetfulness, anger, stress, anxiety, and substance
abuse. Treatment plan issues include the experience or fear of side
effects, high price, inconvenience, and polypharmacy.
The existing body of literature has two limitations. First, the pri-
mary studies linking these factors to nonadherence rely on traditional
epidemiological approaches, where a handful of possible exposures
are linked to the outcome of nonadherence. Several other factors
may be associated with nonadherence that have never been identified
simply because they have not been studied. Second, the body of
literature does not provide a way to determine which of these charac-
teristics impact any given patient in a health care system without
directly attempting to elicit this information from patients. For
instance, a patient's prior experience with side effects may contribute
to subsequent nonadherence, but determining which patients have
experienced side effects is difficult on a large scale.
Though some health exposures that contribute to medication
nonadherence may be found in administrative health data such as
health insurance claims, many of the contributors are more complex
and likely to be found only in the narrative of clinical notes and phone
calls. Notes may provide a much richer picture, including symptoms,
social issues, and life circumstances that could lead to problems with
adherence. A comprehensive review of the electronic health record
(EHR) is not feasible on a large scale, but automated extraction of
concepts from clinical notes using natural language processing (NLP)
software make such an endeavor feasible.
In this paper, we use a concept‐wide association study16 (CWAS)
to identify potential risk factors for medication nonadherence. We
build off of prior work in which we demonstrated that data from the
EHR can provide good predictions of future adherence.17 Unlike tradi-
tional epidemiologic studies that typically test a single association,CWAS enables the discovery of new associations through a paradigm
of simultaneous testing of multiple associations using pre‐specified
covariates. This paradigm was first established in the conduct of
genome‐wide association studies (GWAS) but has been used to
discover associations between diseases and environmental exposures
in environment‐wide association studies (EWAS)18,19 and between a
single genetic variant and multiple phenotypes using phenome‐wide
associations studies (PheWAS).20 A CWAS is useful to establish rela-
tionships between concepts documented in clinical documentation
and health outcomes.2 | METHODS
2.1 | Data source
Our data were drawn from a population of individuals 65 years and
older enrolled in a Medicare Advantage program and receiving care
at one of 24 practice sites of Harvard Vanguard Medical Associates
(HVMA), a large multispecialty community‐based medical group in
eastern and central Massachusetts, between January 2010 and
December 2012. For these individuals, we linked Medicare claims with
structured and unstructured data in the EHR.
From claims data, we extracted data on demographics, all medical
encounters, and diagnostic billing codes. In addition, we used medica-
tion refill data from pharmacy claims to measure adherence. The
HVMA EHR data includes both structured fields, such as demographic
characteristics and diagnostic billing codes, and unstructured fields,
such as text from progress notes, electronic patient instructions, and
patient letters, and telephone encounters (considered collectively as
“clinical notes”). Because this network covers primary care, physician
specialists, and laboratory testing, the EHR data cover nearly all of
the patient's outpatient care encounters and procedures and contain
longitudinal anthropometric and biomarker data.
SINGH ET AL. 1301Prior to receipt and analysis by the research team, clinical notes
were deidentified using several steps. Known identifiers such as patient
and provider names were searched in the clinical notes and replaced
with a series of random letters. All numbers were replaced with “1's.
The remaining text was deidentified using the MITRE Identification
Scrubber Toolkit (MIST), a machine‐learning based deidentification tool
with a demonstrated F‐measure21 in excess of 0.9.2.2 | Study design
We conducted a retrospective cohort study to identify concepts in
clinical notes that are associated with antihypertensive medication
nonadherence. We then grouped the top concepts into clusters based
on interconcept similarity.
We included outpatient adults 65 years or older who filled at least
one prescription for an antihypertensive during 2011‐2012 and were
prevalent users of an antihypertensive medication. The first fill during
this period prior to which patients also had a year of continuous
insurance eligibility was considered the index fill. Prevalent users were
defined as individuals who had at least one antihypertensive filled
during the 365 days preceding the index date. We limited our analysis
to prevalent users because the rates of nonadherence and factors
influencing nonadherence are known to differ among new and preva-
lent users.22 Patients were excluded if they had fewer than 112 days
of follow‐up after the index fill, or if they had fewer than five notes
in the year preceding the index date. We set a threshold of five notes
based on prior experience.16 Patients with fewer than five notes are
unlikely to have enough information in the EHR to allow accurate
judgments about their exposures.
2.3 | Outcome
We defined the outcome of medication nonadherence based on the
proportion of days covered (PDC) in the year following the index fill.
PDC is defined as the proportion of days that the patient had medica-
tion available to him, based on a supply diary that strings together
adjacent fills using the dates and days' supply of each pharmacy claim
for an antihypertensive. We set a threshold of PDC < 0.8 to define
nonadherence based on prior research linking this threshold toFIGURE 1 Analysis of clinical notes in
relation to index fill and outcome assessmentimproved cardiac outcomes and use in other quality measures.23,24
Since patients could fill more than one antihypertensive, we consid-
ered each antihypertensive class that the patient filled separately
and averaged the PDC across classes, which is a valid way of measuring
medication adherence.252.4 | Identification of concepts in clinical notes
Concepts rather than individual words were extracted from clinical
notes so that phrases representing the same idea could be grouped
together when evaluating their association with the outcome (eg,
“CHF” and “congestive heart failure”). Clinical notes consisted of all
unstructured text available in the notes section of the EHR, including
notes and phone calls from physicians of all specialties, nurses, case
managers, and other care providers. The HVMA EHR is primarily an
outpatient record and does not contain admission and inpatient notes.
Concepts were coded as binary variables for each patient. Concepts
were considered present if they were documented at least once in
the clinical notes during the baseline period, and otherwise were
considered absent.
Concepts were extracted from clinical notes in the year prior to the
index prescription date for each patient (Figure 1) using the National
Library of Medicine's MetaMap software26 (2014 version), which
maps phrases to Unified Medical Language System (UMLS) codes
known as concept unique identifiers (CUIs). Negated concepts were
detected and removed using NegEx algorithm.27 Extracted concepts
were restricted to the Systematized Nomenclature of Medicine—
Clinical Terms (SNOMED‐CT) ontology to limit mappings to clinically
relevant concepts. Concepts were not limited by semantic type, so
all types of concepts contained were extracted, including diagnoses,
medications, signs and symptoms, exposures, geographical locations,
and actions taken by a physician or patient. Mapping of phrases to
multiple concepts was allowed. Concepts with less than 1% patient
prevalence were not included in the analysis.
NLP systems may occasionally create erroneous mappings (eg, the
word “Hi” in a phone call note maps to the concept for “Hawaii”).
Instead of reporting the name of the concept intended by the UMLS
definitions, we report the most common phrase for each concept (ie,
we report “Hi” and not “Hawaii”).
TABLE 1 Baseline characteristics of the patients included in the
SINGH ET AL.13022.5 | Identification of covariates
We selected covariates that may confound the relationship between
the exposures and nonadherence, recognizing that these factors may
in fact differ between the tested exposures. We defined baseline
systolic and diastolic blood pressure and creatinine values for each
lab test as the most recent result on or before the index date and esti-
mated glomerular filtration rate (eGFR) was computed using the CKD‐
EPI formula.28 The combined comorbidity score was computed using
claims data in the year prior to the index date.29 We adjusted for
comorbidity because we were concerned that sicker individuals may
have lower rates of adherence due to inability to fill prescription.
We selected the combined comorbidity score because it combines
conditions from the Charlson and Elixhauser measures and was shown
to have similar or slightly better performance in predicting mortality as
compared with either of the individual comorbidity measures in a
Medicare population similar to the population in our study.29
study
Characteristic







Number of patients 4382 3836
Age, y 76.6 (5.4) 76.0 (5.4) <.001
Sex .005
Female 2637 (60.2%) 2189 (57.1%)
Male 1745 (39.8%) 1647 (42.9%)
Race <.001
White 3970 (90.6%) 3101 (80.8%)2.6 | Derivation and validation cohorts
The overall cohort from which our derivation and validation cohorts
were drawn consists of 24 primary care practices. We were concerned
that practice patterns and nonadherence may differ between practices
of different sizes. Thus, we stratified the assignment of patients to the
derivation and validation cohorts at the practice level. Specifically, we
ordered the practices based on their number of patients in our dataset.
We then assigned practices to the derivation and validation set in
alternating order.Black 154 (3.5%) 359 (9.4%)
Hispanic 28 (0.6%) 42 (1.1%)
Other/Unknown 230 (5.2%) 335 (8.7%)
Baseline systolic blood
pressure, mmHg
130.3 (14.8) 130.0 (14.5) .366
Baseline diastolic blood
pressure, mmHg




≥90 480 (11.0%) 460 (12.0%)
60 to 89 2451 (55.9%) 2268 (59.1%)
30 to 59 1328 (30.3%) 1000 (26.1%)
15 to 29 104 (2.4%) 92 (2.4%)
<15 19 (0.4%) 16 (0.4%)
Combined comorbidity
score, median (IQR)
0 (−1 to 2) 0 (−1 to 2) .430
Follow‐up time after
index date, y, median
(IQR)
360 (360‐360) 360 (360‐360) .763
No. of notes in the year
prior to index date,
median (IQR)
74 (43‐120) 76.5 (47‐118) .015
Abbreviation: eGFR, estimated glomerular filtration rate; IQR, interquartile
range.2.7 | Statistical analysis
In the derivation cohort, multivariate logistic regression was performed
to test the association for each of the concepts with medication
nonadherence, adjusting for age, sex, black or Hispanic race, baseline
systolic and diastolic blood pressure, estimated glomerular filtration
rate, and a combined comorbidity score.
We accounted for multiple hypothesis testing using Storey
method, which controls the false discovery rate, defined as the
expected proportion of false positives among all significant hypothe-
ses.30,31 Using this method, P values were transformed into q values.
Odds ratios (OR) and confidence intervals were not adjusted in any
way. Concepts with q values < .05 were reported as potential associ-
ations; this equates to a 5% expected proportion of false positives
among all concepts declared to have associations. The false discovery
rate method was chosen because of its many desirable properties30: it
explicitly controls the error rate of test conclusions among significant
results, scales well in the face of increasing numbers of tests, and has
increased power as compared to the Bonferroni method. After identi-
fying potential associations in the derivation cohort, these were
considered confirmed if the P value in the validation cohort was less
than .05 and the effect was in the same direction.We clustered confirmed predictors into groups using several steps.
First, we calculated pairwise phi correlation coefficients to measure
similarity between concepts and then converted this to a distance
measure by subtracting from 1. Using this distance measure, we ran
a hierarchical clustering algorithm with aggregation using complete
linkage. Any number of clusters can be derived from the result of this
algorithm (up to the number of observations) by “cutting” the hierar-
chical cluster tree at varying depths. We measured several cluster
stability measures (Silhouette, point biserial correlation, Calinski‐
Harabasz, Davies‐Bouldin, Ray‐Turi, and Dunn) for all possible cluster-
ing solutions between five and 20 clusters.32 We selected an optimal
number of clusters based on the cluster stability measures. We
reviewed 10 randomly selected sentences for each concept and
qualitatively assigned labels to each cluster.
SINGH ET AL. 1303Analyses were performed in R 3.3.2 (Vienna, Austria). q Values
were computed using Storey's qvalue R package (available on
Bioconductor).33 Hierarchical clustering was performed using the stats
package and cluster stability metrics were computed using the
clusterCrit package.3 | RESULTS
We identified 8218 patients who met the inclusion and exclusion
criteria (Table 1 and Figure 2) from 24 primary care practices, of whom
2088 (25.4%) were nonadherent to antihypertensives (PDC < 0.8). We
processed 770 353 notes and extracted 32 693 nonnegated concepts
from clinical notes. We removed duplicate phrases and considered
only the 5031 concepts with a prevalence of greater than or equal
to 1%. The median follow‐up period during which we assessed the
PDC was 360 days. We assigned 4382 patients to the derivation
cohort and 3836 to the validation cohort based on their assigned
primary care practice.
Using a false discovery rate threshold of less than 5% (q < .05), we
identified 594 concepts significantly associated with adherence in the
derivation cohort, 583 with nonadherence (OR > 1) and 11 with favor-
able adherence (OR < 1). Of these, 415 concepts had confirmed
associations in the validation cohort based on P value < .05 and con-
cordant OR in the two cohorts. All validated concepts were associated
with nonadherence (OR > 1). Based on several cluster quality mea-
sures (Table S1), we grouped the confirmed associations into 11 clus-
ters (Table 2). The OR, confidence intervals, and q values for individual
concepts are provided in Table S2. Ten randomly selected sentences
from which the cluster descriptions were derived are provided in
Appendix S1.
Cluster 1 includes concepts related to volume depletion (eg, hypo-
tension, IV fluids, dehydration, tachycardia, hydration, lightheadedness,FIGURE 2 Flow diagram of patient selection
for study cohortand dry) and volume overload (eg, 1 pitting edema, pedal edema, lower
extremity edema, BNP [beta natriuretic peptide], low salt diet, diuretic,
CXR [chest X‐ray], and weight gain). Additional concepts in cluster 1
relate to the evaluation of diagnoses that may mimic volume depletion
(eg, WBC [white blood cell count] and urine culture to work‐up infec-
tion) or volume overload (eg, DVT [deep venous thrombosis]). Cluster
2 broadly relates to case management (eg, Case Manager, Case Man-
agement, and nurse case manager), assessment of needs at discharge
(eg, mobility in home, skilled nursing facility, medication teaching,
assistive device, walker, discharged home, plan of care, HOMEASSESS-
MENT, rehab, commode, home exercise program, hospice), mood
disorders (eg, mental illness, Anxiety/depression, and SSRI [selective
serotonin reuptake inhibitor]), and social determinants of health (eg,
Lives with spouse, family support, Social support, upset, afraid, and
compliance). Cluster 3 captures neurological disorders. Cluster 4
includes items related to coordination of care between the physician's
office and the patient (eg, “back” refers to voicemails left for patients
asking them to call back, “Hi” refers to greetings in messages between
care providers, “FW” refers to messages forwarded between care pro-
viders, “pls” is used as shorthand for “please” in the commonly used
phrase “pls call patient,” “letter” refers to letters written to patients,
“Pool” refers to the pool of staff who answer phone calls for patients,
and “adv” is shorthand for patients being “advised”) and documentation
of a variety of symptoms. Cluster 5 is focused on place of residence and
related needs (eg, “hospital bed” in the context of use at home, nursing
home, wheelchair, “assisted” used in the context of assisted living),
refractoriness to treatment (eg, refractory, “unresponsive” used in the
context of unresponsiveness to treatment), and noncompliance. Cluster
6 refers to management of cardiac arrhythmias with warfarin (eg,
“spontaneous” used in the context of spontaneous development of
palpitations/arrhythmias, “prothrombin time” linked to use of warfarin,
“accident” includes a note to patients taking warfarin on what to do if
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SINGH ET AL.1306about the risks of warfarin and need for close monitoring). Cluster 7
refers to patients offered or enrolled in either the AsthmaManagement
Program or COPD Management Program (eg, “pulmonology” refers to
upcoming appointment with pulmonologist, “trained” includes refer-
ences to “specially trained nurses” that comes from an invitation letter
for the Asthma/COPD Management Program, and “expiratory” refers
to increased expiratory time). Cluster 8 includes need for a translator
due to a language barrier and allergies to medications. Cluster 9 refers
to patients taking “blood pressure medicine.” Cluster 10 relates to
counting of cells per high power field (HPF) on urinalysis and measure-
ment of ketones. Cluster 11 refers to language taken from plantar
fasciitis patient instructions.
The 11 clusters we identified include several factors previously
identified by the literature. Our analysis found supporting evidence
for eight of the 12 risk factors for medication nonadherence described
in a widely cited review article1 by Osterberg and Blaschke (Table 3).
Krueger and colleagues13 performed a systematic review that
classified factors affecting adherence into six categories: patient
demographics, family/cultural issues, psychosocial and behavioral
characteristics, treatment plan issues, disease‐related issues, and
health care system issues. We found supportive evidence for five of
these: family/cultural issues (cluster 2), psychological and behavioral
factors (cluster 2), treatment plan issues (clusters 5‐7 and 9), disease‐
related issues (cluster 1), and health care system‐related issues
(clusters 2 and 4). We did not find any clusters related to patient
demographics, but this is not surprising as we adjusted for demo-
graphic characteristics in our analysis.4 | DISCUSSION
This is the first study to use a multiple hypothesis‐testing approach
utilizing text from the clinical notes to identify potential risk factors
for medication nonadherence. Our findings mostly confirm existing
knowledge on medication adherence. Our results are important forTABLE 3 Comparing predictors identified by a review article1 to our not
Predictors in Review Article Related
Presence of psychological problems, particularly depression mental
Presence of cognitive impairment Cognitio
Treatment of asymptomatic disease ‐‐
Inadequate follow‐up or discharge planning ‐‐
Side effects of medication Hypote
dry m
Patient's lack of belief in benefit of treatment refused
Patient's lack of insight into the illness unawar
Poor provider‐patient relationship ‐‐
Presence of barriers to care or medications upset, a
Missed appointments cancel
Complexity of treatment medicat
Cost of medication, copayment, both ‐‐two reasons. First, existing knowledge has been drawn from multiple
clinical studies using carefully assessed exposures and outcomes.
That we were able to partially replicate the findings from published
literature in a single retrospective cohort study using clinical notes
and multiple hypothesis testing is promising because this approach
may be useful for evaluating other clinical questions where the pub-
lished literature is not as rich. Second, the concepts we identified
can be directly used in identifying patients at risk for nonadherence.
While Osterberg and Blaschke's review identified the presence of
psychological problems as a risk factor for nonadherence, our study
provides a mechanism for identifying such patients. Searching the
notes for the phrases “Anxiety/depression,” “mental illness,” “SSRI,”
and “mood” may be effective ways of identifying such patients.
Linking these phrases to clinical decision support would provide a
means to flag high‐risk patients for targeted interventions.
We also identified some surprising associations. We found that
the phrase “Medicare” is linked to nonadherence. While the phrase
would seem to imply that a patient is covered by Medicare, a review
of the sample sentences (Appendix S1) reveals that the concept is
often mentioned in the context of a Medicare notice of noncover-
age, which is delivered to patients as they near completion of
physical rehabilitation. We found the phrase “He” to be linked to
nonadherence, which appears to be used in the clinical documenta-
tion to describe male patients (Appendix S1). Since we adjusted for
sex in our analysis, its significance is likely explained by other con-
texts in which it was used beyond what we found in our review of
sample sentences, as it was found in over 80% of patients. Krueger
and colleagues' systematic review found male providers to be linked
to favorable adherence, so the use of “he” to describe male providers
would not appear to explain this association either. One other sur-
prising finding was that the phrases “Lives with spouse,” “Social sup-
port,” and “family member” were all associated with nonadherence,
contrary to previous literature identified by Krueger and colleagues.
It is possible that clinicians are more likely to assess and document
a patient's living situation if they deem the patient at greater riskes‐driven approach
Phrases Identified Using a Notes‐Driven Approach Clusters
illness, Anxiety/depression, SSRI, mood 1, 2
n, confusion, memory, mental status 2, 3
‐‐
‐‐






fraid, noncompliance, Translator 2, 5, 8
4
ion teaching, Medication review 2
‐‐
SINGH ET AL. 1307for nonadherence. Lastly, the relationship between clusters 9‐11 and
nonadherence is not clear upon review of the randomly sampled
sentences (Appendix S1).
The rising adoption of EHRs and more recent development of
data‐sharing research networks creates an opportunity to systemati-
cally discover predictors of health outcomes from EHRs. We believe
that this approach may be useful especially for the study of rare and
understudied health outcomes and behaviors, where a systematic
review of the literature may not be as fruitful.4.1 | Limitations
As our approach is intended to be hypothesis generating, caution is
needed when interpreting the results because the concepts identified
as predictors may not be used consistently in notes despite evaluation
of example sentences, may represent erroneous mapping by NLP
software, may be confounded, or may represent false positive results
(due to 5% false discovery rate). When concepts have multiple mean-
ings or contexts in the notes, we cannot be certain which of these is
responsible for the overall association with medication nonadherence,
and this may introduce error and limit the interpretability of the
analysis. Confounding and exposure misclassification can be particu-
larly difficult to identify in this type of analysis. For example, the
association between “COLACE” (cluster 2) and nonadherence may be
confounded by “Oxycodone” (also in cluster 2) as stool softeners are
commonly prescribed for prevention of opioid‐induced constipation.
This study draws from a relatively geographically and demographically
homogenous population with a low fraction of non‐white patients, so
its findings may not generalize to other populations. Additionally, our
study was limited by residual confounding. The causal mechanisms
are likely to differ among the multiple exposures tested in this study,
and thus, the covariates included in our analysis may not fully account
for potentially confounders across the breadth of tested exposures.5 | CONCLUSIONS
This approach was successful in identifying previously described and
potentially new predictors of antihypertensive nonadherence using
the clinical narrative as a by‐product of routine care delivery.
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